

GLAXOSMITHKLINE PLC
Form FWP
May 03, 2012

Filed Pursuant to Rule 433

Registration Nos. 333-172621 and 333-172621-01

May 2, 2012

PRICING TERM SHEET

GlaxoSmithKline Capital plc

0.750% Notes due 2015

1.500% Notes due 2017

2.850% Notes due 2022

Fully and unconditionally guaranteed by

GlaxoSmithKline plc

Issuer:	GlaxoSmithKline Capital plc
Guarantor:	GlaxoSmithKline plc
0.750% Notes due 2015:	
Principal Amount:	\$1,000,000,000
Maturity Date:	May 8, 2015
Coupon:	0.750% per annum
Interest Payment Dates:	Semi-annually on May 8 and November 8, commencing November 8, 2012
Day Count Fraction:	30/360
Price to Public:	99.746%
Gross Proceeds to Issuer:	\$997,460,000
Underwriting Discount and Commissions:	0.250%
Net Proceeds to Issuer:	\$994,960,000
Benchmark Treasury:	0.375% due April 15, 2015
Benchmark Treasury Price and Yield:	99-31 / 0.386%
Spread to Benchmark Treasury:	+ 45 bp

Yield to Maturity:	0.836%
Make-Whole Call:	Treasury Rate (as defined in the Prospectus Supplement) plus 10 bp
CUSIP:	377373 AB1
ISIN:	US377373AB16
1.500% Notes due 2017:	
Principal Amount:	\$2,000,000,000
Maturity Date:	May 8, 2017
Coupon:	1.500% per annum
Interest Payment Dates:	Semi-annually on May 8 and November 8, commencing November 8, 2012
Day Count Fraction:	30/360
Price to Public:	99.641%
Gross Proceeds to Issuer:	\$1,992,820,000
Underwriting Discount and Commissions:	0.350%
Net Proceeds to Issuer:	\$1,985,820,000
Benchmark Treasury:	0.875% due April 30, 2017
Benchmark Treasury Price and Yield:	100-7 ³ / ₄ / 0.825%
Spread to Benchmark Treasury:	+ 75 bp
Yield to Maturity:	1.575%
Make-Whole Call:	Treasury Rate (as defined in the Prospectus Supplement) plus 12.5 bp
CUSIP:	377373 AC9
ISIN:	US377373AC98
2.850% Notes due 2022:	
Principal Amount:	\$2,000,000,000
Maturity Date:	May 8, 2022

Coupon:	2.850% per annum
Interest Payment Dates:	Semi-annually on May 8 and November 8, commencing November 8, 2012
Day Count Fraction:	30/360
Price to Public:	99.320%
Gross Proceeds to Issuer:	\$1,986,400,000
Underwriting Discount and Commissions:	0.450%
Net Proceeds to Issuer:	\$1,977,400,000
Benchmark Treasury:	2.000% due February 15, 2022
Benchmark Treasury Price and Yield:	100-20 / 1.929%
Spread to Benchmark Treasury:	+ 100 bp
Yield to Maturity:	2.929%
Make-Whole Call:	Treasury Rate (as defined in the Prospectus Supplement) plus 15 bp
CUSIP:	377373 AD7
ISIN:	US377373AD71
Common Terms:	
Trade Date:	May 2, 2012
Expected Settlement Date:	May 9, 2012 (T+5)
Business Day:	New York and London
Listing:	New York Stock Exchange
Denominations:	\$2,000 x \$1,000
Anticipated Ratings:	A1 by Moody's Investors Service, Inc. A+ by Standard & Poor's Ratings Services
Joint Book-Running Managers:	Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC
Co-Managers:	Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc., Goldman, Sachs & Co., HSBC Securities (USA) Inc., Mizuho Securities USA Inc., RBS Securities Inc. and UBS Securities LLC

Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

The issuer and the guarantor have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer and the guarantor have filed with the SEC for more complete information about the issuer, the guarantor and this offering.

You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll free at 1-888-603-5847 or by emailing barclaysprospectus@broadridge.com, Citigroup Global Markets Inc. toll free at 1-877-858-5407, J.P. Morgan Securities LLC collect at 1-212-834-4533 or Morgan Stanley & Co. LLC toll free at 1-800-718-1649.